Evaluation of Seroconversion Rate Following SARS COV 2 Vaccination in Health Care Workers at Shahid Beheshti University of Medical Sciences

Overview

Journal Avicenna J Med Biotechnol

Specialty Biomedical Engineering

Date 2023 Dec 11

PMID 38078340

Authors

Masoud Alavi

Mohammad Mousavi

Mohammad Jazayeri

Asghar Ebadifar

Affiliations

Soon will be listed here.

Abstract

Background: Vaccines are the most effective way to prevent Coronavirus 2 severe acute respiratory syndrome (SARS-CoV-2). This study examines and compares the efficiency of AstraZeneca, Sinopharm, and Sputnik vaccines and the correlation of antibody response with age, sex, and history of corona disease in employees of Shahid Beheshti University of Medical Sciences.

Methods: 202 participants were included, of which 82 were administered the Astra-Zeneca, 59 were given the Sinopharm, and 61 were given the Sputnik vaccine. SARSCoV-2 IgM and IgG antibody levels were checked four weeks after passing the second dose of all three vaccines using the enzyme-linked immunosorbent assay (ELISA) technique.

Results: There was no significant difference between the amount of IgM and IgG antibodies among three vaccines (p=0.056). For all three vaccines, gender and age did not significantly affect the amount of IgM and IgG antibodies. The history of infection with COVID-19 increased the antibody response (p>0.5).

Conclusion: The titer of IgM and IgG antibodies were not statistically significantly different. The IgM and IgG antibodies produced by vector-based vaccines are higher than the Sinopharm vaccine. Gender did not affect the produced antibody titer. No significant linear relationship was found between age and antibody titer. In people from this study who received two doses of the AstraZeneca vaccine and had a corona history, the average amount of both IgM and IgG antibodies was measured more than the other participants.

References

Forni G, Mantovani A . COVID-19 vaccines: where we stand and challenges ahead. Cell Death Differ. 2021; 28(2):626-639. PMC: 7818063. DOI: 10.1038/s41418-020-00720-9. View

Li Y, Chi W, Su J, Ferrall L, Hung C, Wu T . Coronavirus vaccine development: from SARS and MERS to COVID-19. J Biomed Sci. 2020; 27(1):104. PMC: 7749790. DOI: 10.1186/s12929-020-00695-2. View

Sarker P, Akhtar E, Kuddusi R, Alam M, Haq M, Hosen M . Comparison of the Immune Responses to COVID-19 Vaccines in Bangladeshi Population. Vaccines (Basel). 2022; 10(9). PMC: 9504987. DOI: 10.3390/vaccines10091498. View

Batty C, Heise M, Bachelder E, Ainslie K . Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection. Adv Drug Deliv Rev. 2020; 169:168-189. PMC: 7733686. DOI: 10.1016/j.addr.2020.12.006. View

Pushparajah D, Jimenez S, Wong S, Alattas H, Nafissi N, Slavcev R . Advances in gene-based vaccine platforms to address the COVID-19 pandemic. Adv Drug Deliv Rev. 2021; 170:113-141. PMC: 7789827. DOI: 10.1016/j.addr.2021.01.003. View

Nagy A, Alhatlani B . An overview of current COVID-19 vaccine platforms. Comput Struct Biotechnol J. 2021; 19:2508-2517. PMC: 8076774. DOI: 10.1016/j.csbj.2021.04.061. View

Logunov D, Dolzhikova I, Shcheblyakov D, Tukhvatulin A, Zubkova O, Dzharullaeva A . Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021; 397(10275):671-681. PMC: 7852454. DOI: 10.1016/S0140-6736(21)00234-8. View

Wei J, Stoesser N, Matthews P, Ayoubkhani D, Studley R, Bell I . Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom. Nat Microbiol. 2021; 6(9):1140-1149. PMC: 8294260. DOI: 10.1038/s41564-021-00947-3. View

Grzelak L, Temmam S, Planchais C, Demeret C, Tondeur L, Huon C . A comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations. Sci Transl Med. 2020; 12(559). PMC: 7665313. DOI: 10.1126/scitranslmed.abc3103. View

10.

Anvari E, Talepoor A, Vakili M, Karimi N, Ataollahi M, Najafi G . Comparison of the Antibody Responses Following Vaccination with AstraZeneca and Sinopharm. Iran J Immunol. 2022; 19(3):321-329. DOI: 10.22034/iji.2022.94298.2300. View

11.

Wang J, Peng Y, Xu H, Cui Z, Williams 3rd R . The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation. AAPS PharmSciTech. 2020; 21(6):225. PMC: 7405756. DOI: 10.1208/s12249-020-01744-7. View

12.

Yang H, Costa V, Racine-Brzostek S, Acker K, Yee J, Chen Z . Association of Age With SARS-CoV-2 Antibody Response. JAMA Netw Open. 2021; 4(3):e214302. PMC: 7985726. DOI: 10.1001/jamanetworkopen.2021.4302. View

13.

Melief C, van Hall T, Arens R, Ossendorp F, van der Burg S . Therapeutic cancer vaccines. J Clin Invest. 2015; 125(9):3401-12. PMC: 4588240. DOI: 10.1172/JCI80009. View

14.

Chan J, Yuan S, Kok K, To K, Chu H, Yang J . A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020; 395(10223):514-523. PMC: 7159286. DOI: 10.1016/S0140-6736(20)30154-9. View

15.

Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P . Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020; 397(10269):99-111. PMC: 7723445. DOI: 10.1016/S0140-6736(20)32661-1. View

16.

Vyas A, Varma V, Garg G, Gupta P, Trehanpati N . The role and delicate balance of Host Immunity in Coronavirus Disease-19. Iran J Immunol. 2021; 18(1):1-12. DOI: 10.22034/iji.2021.88526.1874. View

17.

St John A, Rathore A . Early Insights into Immune Responses during COVID-19. J Immunol. 2020; 205(3):555-564. DOI: 10.4049/jimmunol.2000526. View

18.

Yu S, Chen K, Fang L, Mao H, Lou X, Li C . Comparison and Analysis of Neutralizing Antibody Levels in Serum after Inoculating with SARS-CoV-2, MERS-CoV, or SARS-CoV Vaccines in Humans. Vaccines (Basel). 2021; 9(6). PMC: 8229804. DOI: 10.3390/vaccines9060588. View

19.

Mulligan M, Lyke K, Kitchin N, Absalon J, Gurtman A, Lockhart S . Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020; 586(7830):589-593. DOI: 10.1038/s41586-020-2639-4. View

20.

Khoury D, Cromer D, Reynaldi A, Schlub T, Wheatley A, Juno J . Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021; 27(7):1205-1211. DOI: 10.1038/s41591-021-01377-8. View